Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;17(3):1563-1568.
doi: 10.3892/etm.2018.7125. Epub 2018 Dec 21.

Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser

Dingding Wang  1 , Xiaoyi Wang  1 , Kunfang Wu  1 , Juanjuan Wang  1 , Guihua Xu  1 , Zilin Chen  1
Affiliations

Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser

Dingding Wang et al. Exp Ther Med. 2019 Mar.

Abstract

The aim of this study was to evaluate the clinical efficacy of an intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy in the treatment of different degrees of central retinal vein occlusion (CRVO). A total of 112 CRVO patients including 25 cases of trunk occlusion, 50 cases of branch occlusion and 37 cases of hemiretinal vein-occlusion were enrolled in this study. Patients were treated with an intravitreal injection of 0.5 mg ranibizumab, followed by argon ion laser photocoagulation therapy after 7 days. Patients were followed up for 6 months and the best corrected visual acuity (BCVA), central retinal thickness (CRT), macular edema, and surgical complications were compared. Compared with the control treated with 0.5 mg ranibizumab, the BCVA and macular edema improved while CRT was significantly reduced in all groups treated with 0.5 mg ranibizumab combined with the argon ion laser. Furthermore, no obvious complications were observed in these groups and the effects of ranibizumab combined with argon ion laser photocoagulation on branch occlusion group were the best. Intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy has better safety and effectiveness in the treatment of different degrees of CRVO. The trial registration number is 2015-318 and date of registration is 12/10/2015.

Keywords: argon ion laser; central retinal vein occlusion; ranibizumab; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Comparison of BCVA in follow-up. In 1, 3 and 6 months of follow-up, BCVA was evaluated in trunk occlusion group, branch occlusion group, hemi-occlusion group treated with ranibizumab or ranibizumab combined with argon ion laser. *P<0.05 and **P<0.01 vs. the control. BCVA, best corrected visual acuity.
Figure 2.
Figure 2.
Comparison of CRT in follow-up (µm). In 1, 3 and 6 months of follow-up, CRT was evaluated in trunk occlusion group, branch occlusion group, hemi-occlusion group treated with ranibizumab or ranibizumab combined with argon ion laser. *P<0.05 and **P<0.01 vs. the control. CRT, central retinal thickness.
Figure 3.
Figure 3.
Comparison of the remission rate of macular edema in follow-up (%). In 6 months of follow-up, the remission rate of macular edema was evaluated in trunk occlusion group, branch occlusion group, hemi-occlusion group treated with ranibizumab or ranibizumab combined with argon ion laser. **P<0.01 vs. the control.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wittström E. Central retinal vein occlusion in younger Swedish adults: Case reports and review of the literature. Open Ophthalmol J. 2017;11:89–102. doi: 10.2174/1874364101711010089. - DOI - PMC - PubMed
    1. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: An approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38:904–910. doi: 10.1111/j.1445-5994.2008.01720.x. - DOI - PubMed
    1. Nroev VV. Modern aspects of diabetic retinopathy and diabetic macularoedema treatment. Vestn Ross Akad Med Nauk. 2012;1:61–65. - PubMed
    1. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. J Ophthalmol. 2014;2014:724780. doi: 10.1155/2014/724780. - DOI - PMC - PubMed
    1. Kuo JZ, Lai CC, Ong FS, Shih CP, Yeung L, Chen TL, Chen KJ, Wu WC. Central retinal vein occlusion in a young Chinese population: Risk factors and associated morbidity and mortality. Retina. 2010;30:479–484. doi: 10.1097/IAE.0b013e3181b9b3a0. - DOI - PMC - PubMed